Wells Fargo Upgrades Sutro Biopharma to Overweight, Raises Price Target to $27

Benzinga Newsdesk www.benzinga.com Positive 93.3%

Neg 0% Neu 0% Pos 93.3%

Wells Fargo analyst Eva Fortea Verdejo upgrades Sutro Biopharma (NASDAQ:STRO) from Equal-Weight to Overweight and raises the price target from $8 to $27.